HENDERSON, Nev., Jan. 22, 2018 (GLOBE NEWSWIRE) — United Health Products, Inc. (UHP) (OTCPK:UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that, following a face-to-face meeting between FDA and key UHP representatives, it will pursue its PMA class III filing under the FDA’s CtQ Pilot program for use in internal surgical procedures. Further, the company has decided to withdraw from its class II extension of use application with the FDA. It was determined that the PMA application allows a much broader range of indication than the prior 510K class II of expanded usage.
About United Health Products, Inc.
United Health Products (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com.
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
United Health Products, Inc.
PAN Consultants Ltd.